How many drugs treat Kaposi's sarcoma?

Drug Landscape tracks 10 marketed treatments for Kaposi's sarcoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/kaposi-s-sarcoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Kaposi's sarcoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kaposi's sarcoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Kaposi's sarcoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Taxol	paclitaxel	Pfizer	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Taxol	nab-paclitaxel	Pfizer	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Daunorubicin Hydrochloride	daunorubicin	Meiji Seika Pharma Co., Ltd	Anthracycline Topoisomerase Inhibitor	Histone deacetylase 6	1979-01-01
Liposomal Doxorubicin	liposomal-doxorubicin	Pfizer	doxorubicin	72 kDa type IV collagenase	1974-01-01
Doxorubicin Hydrochloride	doxorubicin	Pfizer	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Vinblastin	Vinblastin	The Lymphoma Academic Research Organisation		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1
Taxol	Taxol	M.D. Anderson Cancer Center		Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5
Abraxane	Abraxane	The First Affiliated Hospital with Nanjing Medical University		Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5
Adriamycin	Adriamycin	Johann Wolfgang Goethe University Hospital		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Hydroxydaunorubicin	Hydroxydaunorubicin	University of Colorado, Denver		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 5 drugs in Kaposi's sarcoma
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in Kaposi's sarcoma
Johann Wolfgang Goethe University Hospital · 1 drug in Kaposi's sarcoma
M.D. Anderson Cancer Center · 1 drug in Kaposi's sarcoma
Meiji Seika Pharma Co., Ltd · 1 drug in Kaposi's sarcoma
The First Affiliated Hospital with Nanjing Medical University · 1 drug in Kaposi's sarcoma
The Lymphoma Academic Research Organisation · 1 drug in Kaposi's sarcoma
University of Colorado, Denver · 1 drug in Kaposi's sarcoma
Chipscreen Biosciences, Ltd. · 1 drug in Kaposi's sarcoma
Weill Medical College of Cornell University · 1 drug in Kaposi's sarcoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Kaposi's sarcoma:

Cite this brief

Drug Landscape (2026). Kaposi's sarcoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/kaposi-s-sarcoma. Accessed 2026-06-10.

Kaposi's sarcoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing